Vera Therapeutics, Inc. (VERA)

Market Cap	2.17B
Revenue (ttm)	n/a
Net Income (ttm)	-95.99M
Shares Out	54.92M
EPS (ttm)	-2.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	842,186
Open	39.63
Previous Close	40.01
Day's Range	38.83 - 40.71
52-Week Range	6.07 - 50.78
Beta	1.05
Analysts	Strong Buy
Price Target	32.29 (-18.21%)
Earnings Date	May 9, 2024

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA

Analyst Forecast

According to 8 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price forecast is $32.29, which is a decrease of -18.21% from the latest price.

Price Target

$32.29

(-18.21% downside)

Analyst Consensus: Strong Buy